---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-059031"
form_type: "8-K"
ticker: "ZURA"
cik: "0001855644"
company_name: "Zura Bio Ltd"
filed_at: "2024-05-09T23:59:59+00:00"
generated_at: "2026-06-02T07:05:51.776273+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Zura Bio Q1 net loss $7.7M; cash $89.8M, closes $112.5M placement, appoints CEO

## Summary
- Net loss $7.7M vs $9.6M prior year; cash $89.8M at March 31, 2024.
- Closed oversubscribed $112.5M private placement in April 2024 from institutional investors.
- Appointed Robert Lisicki as CEO and Kiran Nistala as CMO.
- On track for Phase 2 trials: tibulizumab in SSc Q4 2024, HS Q2 2025.
- Cash runway extended through 2027 with placement factored in.

## SEC filing metadata
- accession: 0001104659-24-059031
- form_type: 8-K
- ticker: ZURA
- cik: 0001855644
- company_name: Zura Bio Ltd
- filed_at: 2024-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1855644/000110465924059031/0001104659-24-059031-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1855644/000110465924059031/tm2413941d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-059031
- JSON: https://secwatch.observer/filing/0001104659-24-059031.json
- Plain text: https://secwatch.observer/filing/0001104659-24-059031.txt

## Key facts
- Earnings Releases
  Zura Bio Ltd reported first quarter 2024 results: net income $7.7 million.
  - Period: first quarter 2024
  - Net income: $7.7 million
  - Result: reported results
  source text: Net loss for the first quarter of 2024 was $7.7 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1855644/000110465924059031/0001104659-24-059031-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.